Table 1.
Baseline Characteristics of the Study Participants
| Characteristics | Dabigatran (n = 122) | Warfarin (n = 122) |
|---|---|---|
| Age, y | 70.0 ± 11.4 | 70.1 ± 10.3 |
| Male sex | 68 (55.7%) | 64 (52.5%) |
| Smoking | ||
| Yes | 9 (7.4%) | 9 (7.4%) |
| No | 59 (48.4%) | 67 (54.9%) |
| Ex‐smokers | 30 (24.6%) | 23 (18.9%) |
| Unknown | 24 (19.7%) | 23 (18.9%) |
| CHADS2 score | 2.48 ± 1.34 | 2.32 ± 1.47 |
| 0 | 7 (5.7%) | 11 (9.0%) |
| 1 | 23 (18.9%) | 34 (27.9%) |
| ≥2 | 92 (75.4%) | 77 (63.1%) |
| Medical history | ||
| Hypertension | 85 (69.7%) | 77 (63.1%) |
| Diabetes mellitus | 35 (28.7%) | 42 (34.4%) |
| Heart failure | 31 (25.4%) | 38 (31.1%) |
| Hyperlipidemia | 40 (32.8%) | 36 (29.5%) |
| Ischemic heart diseases | 30 (24.6%) | 25 (20.5) |
| Prior myocardial infarction | 9 (7.4%) | 12 (9.8%) |
| Previous stroke or transient ischemic attack | 53 (43.4%) | 39 (32.0%) |
| Dyspepsia | 24 (19.7%) | 21 (17.2%) |
| Chronic kidney disease | 9 (7.4%) | 13 (10.7%) |
| Medications at baseline | ||
| Aspirin | 21 (17.2%) | 30 (24.6%) |
| ACE inhibitors or ARB | 63 (51.6%) | 51 (41.8%) |
| β‐blocker | 65 (53.3%) | 65 (53.3%) |
| Calcium channel blocker (dihydropyridine) | 37 (30.3%) | 20 (16.4%) |
| Calcium channel blocker (nondihydropyridine) | 11 (9.0%) | 14 (11.5%) |
| Amiodarone or dronedarone | 4 (3.3%) | 14 (11.5%) |
| Statins | 62 (50.8%) | 52 (42.6%) |
| Proton pump inhibitor | 19 (15.6%) | 19 (15.6%) |
| H2‐receptor antagonist | 54 (44.3%) | 52 (42.6%) |
| Antacid | 9 (7.4%) | 5 (4.1%) |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin‐receptor blocker.